Announcement on the Adjustment of the Construction Period for the Smart Factory Project
The company and all members of the board of directors guarantee the truthfulness, accuracy, and completeness of the disclosed information, and there are no false records, misleading statements, or significant omissions.
CR Pharma Bio-engineering Co., Ltd. (hereinafter referred to as the Company or CR Pharma Bio-engineering) held the 18th meeting of the 8th Board of Directors on March 19, 2026, and deliberated and passed the "Proposal on the Adjustment of the Construction Period for the Smart Factory Project." Through re-optimization and sorting of project investment, implementing strategies of phased construction and phased investment, capital occupation is effectively reduced, idle fixed assets are reduced, and fund utilization efficiency is improved. At the same time, in conjunction with the "Code for Quality Control of Pharmaceutical Production (2010 Revision) - Appendix for Sterile Drugs (Draft for Comments)" released in March 2025 and the "Standard for Construction and Acceptance of Pharmaceutical Industry Clean Rooms" released in September 2025, construction standards are further improved. Combined with the "Technical Guiding Principles for Site Change Research of Marketing Blood Products (Trial)" released in May 2025, the arrangement for process validation pilot production is further standardized. The project completion and acceptance time will be postponed by 3 months, with completion expected in June 2026, and official production commencement in June 2028 after the production site change is approved.
According to the "Shenzhen Stock Exchange GEM Stock Listing Rules," "Shenzhen Stock Exchange Listed Company Self-Regulatory Supervision Guidelines No. 2 - Standardized Operation of GEM Listed Companies," and the "Company Articles of Association," this matter does not require submission to the company's shareholders' meeting for deliberation.
The specific situation is hereby announced as follows:
One, Basic Situation of Raised Funds
Upon approval by the China Securities Regulatory Commission's "Approval for CR Pharma Bio-engineering Co., Ltd. to Issue Shares Privately" (Securities Regulatory License [2018] No. 117), CR Pharma Bio-engineering issued 32,247,662 shares to 4 specific investors at an issue price of 31.01 yuan/share, with a total raised fund of 999,999,998.62 yuan. After deducting issuance expenses of 10,744,000.00 yuan, the net raised fund is 989,255,998.62 yuan. The aforementioned raised funds have been audited by Jiangsu Gongzheng Tianye Certified Public Accountants (Special General Partnership) and have issued the "Capital Verification Report" (Su Gong W[2018]B041).
To standardize the management and use of the company's raised funds and protect the rights and interests of investors, the company has adopted a special account storage system for the raised funds. After the raised funds are received, they are all deposited in the special raised funds account approved by the Board of Directors, and a "Tripartite Supervision Agreement for Raised Funds" has been signed with the sponsor and the commercial bank where the raised funds are deposited.
Two, Situation of Raised Funds Investment Projects
(One) Situation of Raised Funds Special Account Storage
As of December 31, 2025, the balance of the company's special account for raised funds is RMB 28,783,009.95 yuan. The account details are as follows:
| Opening Bank | Bank Account Number | RMB Amount (yuan) | Deposit Type |
|---|---|---|---|
| China CITIC Bank, Nanchang Branch | 8115701013100148137 | 4,295,794.57 | Current |
| Industrial and Commercial Bank of China, Fuzhou Branch | 1511200929100050264 | 24,487,215.38 | Current |
| Total | 28,783,009.95 |
(Two) Situation of Raised Funds Usage and Balance
As of December 31, 2025, the cumulative amount of raised funds used for the "Blood Products Smart Factory (Phase I) Construction Project" is RMB 499,069,217.81 yuan, and the balance of the raised funds special account is 28,783,009.95 yuan. The specific usage is as follows: